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Summary We have studied the growth inhibition, DNA synthesis inhibition and cell incorporation of the new
anthracycline 4'-iodo-4'-deoxydoxorubicin (4'-iododoxorubicin) and of its 13-dihydroderivative in a model of
doxorubicin-sensitive and -resistant rat C6 glioblastoma cells; results were compared to those obtained with
doxorubicin and doxorubicinol in the same model. 4'-Iododoxorubicin was 7.5 times more potent than
doxorubicin on the wild cell line and 45 times on the doxorubicin-resistant line, indicating that cross-resistance
was only partial between the two drugs. Whereas doxorubicinol presented only a very faint cytotoxic activity,
4'-iododoxorubicinol retained the same activity as the parent drug against sensitive cells and a lower activity
against resistant cells. DNA synthesis inhibition occurred for much higher doses than growth inhibition in the
sensitive cells, but for similar doses in resistant cells. In both cell lines, 4'-iododoxorubicin and its metabolite
were incorporated to a higher extent than doxorubicin and doxorubicinol respectively. Incorporation of
metabolites was always lower than that of their parent compound. We have studied the metabolism of
doxorubicin and 4'-iododoxorubicin by sensitive and resistant cells; only traces (< 5%) of metabolites were
identified in the cells as well as in the culture medium. A new cell line was selected for resistance in the
presence of low amounts of 4'-iododoxorubicin. It presented a 6-fold resistance to 4'-iododoxorubicin and an
85-fold resistance to doxorubicin. Doxorubicin incorporation was markedly reduced in this cell line while
4'-iododoxorubicin was incorporated to the same extent as in the sensitive line. Measurements of drug efflux
were performed in the three cell lines. No significant difference was exhibited between the efflux of doxorubicin
and that of 4'-iododoxorubicin in each cell line; these effluxes were very rapid in the doxorubicin-selected
resistant line, slow in the wild line and intermediate in the 4'-iododoxorubicin-selected line.
4'-Iodo-4'-deoxydoxorubicin (4'-iododoxorubicin) is a new
anthracycline derivative originating from a chemical modifi-
cation of doxorubicin obtained by Barbieri et al. (1987).
Modifications at position 4 of the amino-sugar have already
led to the clinically useful analogue epirubicin (Ganzina,
1983) and seem of importance for the development of new
analogues. Barbieri et al. (1987) recently reported on the
chemical and biological properties of 4'-iododoxorubicin in
several cell lines. In a pharmacokinetic study in mice
(Formelli et al., 1987), it was shown that it underwent exten-
sive metabolism to a 13-dihydro-derivative (4'-iodo-4'-deoxy-
doxorubicinol), and this has been recently confirmed in
humans during two phase I studies (Gianni et al., 1989;
Robert et al., 1989). The possible importance of this new
drug in cancer chemotherapy prompted us to investigate the
behaviour of this drug and its metabolite in our model of
doxorubicin-sensitive and -resistant rat glioblastoma cells.
Moreover, in order to compare the mechanisms involved in
anthracycline resistance, we have developed with the same
cell strain a variant line resistant to 4'-iodo-4'-deoxydoxo-
rubicin. We present here results concerning growth inhi-
bition, DNA synthesis inhibition, drug incorporation of 4'-
iododoxorubicin and its 13-dihydroderivative as compared to
doxorubicin and doxorubicinol, in our models of wild and
drug-resistant rat glioblastoma cells. We have also studied
the amplification and expression of the mdr gene in the three
cell lines. In addition, the metabolism of doxorubicin and
4'-iododoxorubicin was studied in our cell variants, as well as
the efflux of doxorubicin and 4'-iododoxorubicin.
Material and methods
Drug
4'-Iodo-4'-deoxydoxorubicin and its 13-dihydroderivative, as
well as doxorubicinol, were provided by Farmitalia-Carlo
Erba; doxorubicin and vincristine were provided by Labora-
toire Roger-Bellon. The drugs were dissolved in sterile pure
water at concentrations of I - 10 mg ml-' and stored at
-20°C.
Cell culture
The C6 rat glioblastoma line and its doxorubicin-resistant
counterpart (Vrignaud et al., 1986a) were routinely cultivated
in Petri dishes (Nunc) with Dulbecco's modified Eagle
medium supplemented with 10% fetal calf serum (Seromed),
at 37'C in a humidified atmosphere containing 5% CO2.
The cultures were replicated each week and the medium was
changed each two or three days, depending on the cell
density. Doxorubicin-resistant cells had been selected by
exposure to stepwise increasing amounts of doxorubicin and
grew permanently in the presence of 0.5 tgml1' of doxo-
rubicin in the culture medium (C6 0.5 E).
A subline of C6 cells resistant to 4'-iodo-4'-deoxydoxo-
rubicin was obtained from the wild strain by the same
method as that used for doxorubicin resistance. However, it
was necessary to begin with minute amounts of drug for
initiating the resistance and to increase very slowly the
amount of drug present in the culture medium. It had been
possible to obtain the doxorubicin-resistant line with steps of
10 passages each at the successive concentrations of 0.03, 0.1,
0.3 and 0.5 or 1.0 ig of doxorubicin per ml medium (Vrig-
naud et al., 1986b). It was necessary with 4'-iododoxorubicin
to begin with 0.005 lg ml-'; one increment to 0.01 jg ml
was possible after 20 passages, but no further increase of the
selection dose was possible thereafter. This line is called
thereafter C6 IDX-R.
Evaluation ofgrowth inhibition
Appropriate numbers of cells were seeded in 10 or 20cm2
Petri dishes with 3 or 5 ml medium, so that 3 days later the
number of cells reached approximately 5 x 105 cells per dish.
The medium was than substituted by a new medium contain-
ing various concentrations of drug (0.0032-1I00 g ml1') and
incubation was performed for 2 h at 37'C. For vincristine
cytotoxicity, this incubation was performed for the duration
of a complete cell cycle. After drug exposure, cell monolayers
were washed twice with sterile 0.15 M NaCl, replaced by
normal medium and further incubated for a time correspond-
ing to two cell cycles (48-96 h according to the cell line). For
estimation of cell numbers, monolayers were washed twice
with 0.15 M NaCl and suspended in culture medium with the
help of a trypsin solution. Cells were counted in an auto-
matic hemocytometer (Royco-Cell Crit 920A). All measure-
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ments were performed in triplicate and three independent
experiments were performed. Growth inhibition was ex-
pressed at GICm, i.e. the concentration of drug causing 50%
reduction of cell numbers, as compared to controls incubated
simultaneously in the absence of drug.
Evaluation ofdrug incorporation, drug efflux and DNA
synthesis inhibition
Appropriate numbers of cells were seeded in 10 or 20cm2
Petri dishes with 3 or 5 ml medium, so that 4 days later the
number of cells reached approximately 2 x 106 per dish. The
medium was then substituted by new medium containing
various concentrations of drugs (0.032-100 tg ml-') and the
dishes were incubated at 37°C for 2 h. One hour before the
end of drug exposure, I tLCi of3H-methyl-thymidine per dish
was added. Then, the cell monolayers were washed twice with
0.15M NaCl, harvested after gentle stirring and pelleted at
3,000 r.p.m. for 5 min. These steps were rapidly performed in
order to avoid any drug efflux; 0.5 ml bidistilled water and
0.5 ml 40% trichloroacetic acid were successively added and
the samples were kept at 4°C overnight, then centrifuged
during 30 min at 3,000 r.p.m. The acid-soluble part was used
to evaluate intracellular concentration by fluorometry (Jobin
Yvon NE 1 spectrofluorometer) with excitation and emission
wavelengths set at the maximum fluorescence of drug in
the trichloroacetic solution (around 470 nm for excitation
and 550 nm for emission). It was not possible by this tech-
nique to make a distinction between free drug and tightly
bound or loosely bound drug. The acid-insoluble pellet was
solubilised with 1 M NaOH and used to evaluate both protein
content (Lowry et al., 1951) and 3H radioactivity in a Beck-
man LS 1207 liquid scintillation spectrometer. All incuba-
tions were performed in triplicate and three independent
experiments were performed. In all cases, the incorporation
of 3H-methyl-thymidine was referred to controls realised in
the same conditions and incubated without drug; it was thus
possible to define a DNA synthesis inhibition as TIC50, i.e.
the concentration of drug providing a 50% decrease of 3H-
thymidine incorporation.
Drug efflux was evaluated in the same conditions for both
drugs in each cell line. Culture medium was substituted by
new medium containing an appropriate quantity of drug in
order to obtain an intracellular concentration of about
1 gsg mg-' protein after 2 h of exposure at 37°C in the CO2
incubator. The cells were then rapidly washed with fresh
medium, and reincubated in the same conditions for 5, 10,
20, 30 min, 1, 2 and 4 h. Drug incorporation was then
measured as described.
Metabolism ofdoxorubicin and 4'-iododoxorubicin
The metabolism of both drugs was evaluated after 2 h of
contact of the cells with 1 or 10ytg ml-' of drug. After
incubation, the cells were recovered, pelleted and anthracy-
clines were extracted by the technique of Baurain et al.
(1979). Briefly, cell homogenates were brought to alkaline pH
by addition of 1 vol. of pH 9.8 borate buffer, and immed-
iately extracted with 18 vol. of chloroforme/methanol 4/1
(vol./vol.). The mixture was shaken and centrifuged; the
lower organic layer was evaporated to dryness under a
stream of nitrogen and dissolved in a small amount of the
mobile phase of the liquid chromatograph. High performance
liquid chromatography was performed with a model 6000 A
Waters pump and a Waters U6K injector. The stationary
phase was microbondapak-phenyl (10lm) (Waters) packed
in 30 x 0.4 cm metal columns. The mobile phase was a mix-
ture of acetonitrile and 0.1% ammonium formate buffer
(34/66, vol./vol.), nearly as described by Israel et al. (1978).
Detection was achieved thanks to a Perkin-Elmer model LS1
spectrofluorometer. Cell culture media could be injected
directly on the column.
Identification and expression ofP-glycoprotein gene
The probe used in this work was a generous gift from
P. Borst and A. van der Bliek (National Cancer Institute,
Amsterdam). The probe Cp 28 was prepared from a cDNA
library established from the multidrug-resistant chinese ham-
ster ovary cell line CHRC5, inserted in the Pst I site of the
pUC9 vector (Van der Bliek et al., 1986). We have intro-
duced the plasmid in a competent E. coli C600 strain accord-
ing to Hanahan (1983). Plasmid DNA was prepared, digested
by Pst I and the probe Cp28 isolated. Labelling was per-
formed on 50 ng of cDNA with 0.1 mCi _-32P-dCTP by the
Multiprime method (Amersham).
High molecular weight DNAs were extracted from sensi-
tive and resistant lines according to Maniatis et al. (1982),
quantitated by spectroscopy at 260 nm and digested with Eco
RI restriction endonuclease (Boehringer-Mannheim). DNA
digests (10fg) were electrophorised in 0.8% agarose gels,
denatured in NaOH 0.5 M, 1.5 M NaCl, neutralised with
sodium acetate 3 M, pH 5.5, and transferred on Hybond N
membranes (Amersham) (Southern, 1975). The filters were
pre-hydridised for 20 h at 42°C in a solution containing 50%
formamide, 0.75 M NaCl, 0.075 M trisodium citrate, 10 x
Denhardt solution, 100figml-' denatured salmon sperm
DNA, 0.1% SDS, 1 mM EDTA, 0.05 M sodium phosphate
buffer pH 6.5. The hydridisations were conducted in the same
medium for 48 h at 42°C with the labelled probe after its
denaturation at 100°C for 10 min. After several washes at
room temperature and a final wash at 65°C with 0.015 M
NaCl, 0.0015 M sodium citrate, 0.1% SDS, autoradiography
was performed at -70°C on Hyperfilm MP (Amersham).
Total cellular RNAs were extracted in 6 M guanidium isothio-
cyanate according to Chirgwin et al. (1979), resuspended in
10 mM Tris, pH 7.4, 1% SDS, 1 mM EDTA after ultracentri-
fugation on caesium chloride and purified by extraction with
chloroform/butanol 4/1 (Schweitzer & Goerttler, 1980). RNA was
quantified by absorption spectroscopy at 260 nm and results
confirmed by visualisation on an ethidium bromide stained gel
obtained in 1% agarose and 6% formaldehyde; 20tLg of total
RNAs were size-fractioned by electrophoresis in a 1% agarose,
6% formaldehyde gel, soaked for 30 min in 3 M NaCl, 0.3 M
trisodium citrate, and transferred to Hybond N membrane
(Thomas, 1980). Membrane treatment, hybridisation, washes
and autoradiography were performed as described for DNA.
Only those samples which gave the highest hybridisation spots
were chosen for quantification by densitometry.
Results
P-glycoprotein gene expression in the cell lines
Southern blots revealed a faint amplification of the P-
glycoprotein gene (2-3 times) in the C6 line selected in
doxorubicin (C6 0.5 E), whereas the line selected in 4'-
iododoxorubicin presented no amplification at all of the
gene.
Northern blots revealed in both lines an overexpression of
the P-glycoprotein gene; it could be evaluated semi-quantita-
tively as 10-fold the level of the wild line in doxorubicin-
resistant cells (C6 0.5 E) and as 5-fold in 4'-iododoxorubicin-
resistant (C6 IDX-R).
Growth inhibition
4'-Iododoxorubicin provided a higher growth inhibition of
the C6 wild strain than doxorubicin did (Table I). The new
halogeno compound was about 7.5 times more potent than
the original anthracycline. When studied in the C6 doxo-
rubicin-resistant line, the higher potency of 4'-iododoxoru-
bicin was even more pronounced (45 times) showing that
cross-resistance between the two drugs was only partial; the
doxorubicin-resistant cells were 400 times resistant to doxo-
rubicin and 70 times to 4'-iododoxorubicin. Interestingly, the
new variant selected for resistance to 4'-iododoxorubicin was
only weakly resistant to this drug (6 x) and much more
resistant to doxorubicin (85 x). Studies of growth inhibition
by vincristine revealed that both anthracycline-resistant lines
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TableI GrowthinhibitionofC6glioblastomacellsand theirresistantvariantsbyvincristine,doxorubicin,
4'-iododoxorubicin and their 13-dihydroderivatives
GIC50 (PAM)
Resistance Resistance
C6 sensitive cells C6 0.5 E factor C6 IDX-R factor
Doxorubicin 0.131 + 0.017 52.2 ± 5.7 398 11.1 ± 2.5 85
4'-Iododoxorubicin 0.017 ± 0.004 1.17 ± 0.28 69 0.112 ± 0.043 6
Vincristine 0.025 0.001 0.380 0.007 15 0.17 ± 0.05 7
Doxorubicinol 4.25 ± 1.90 > 200 > 47 -
4'-Iododoxorubicinol 0.020 ± 0.007 1.88 ± 0.41 94
Values are means ± s.e.m. of three independent experiments made in triplicate.
were also resistant to vincristine, indicating a multidrug-
resistant phenotype of both lines.
Growth inhibition induced by the 13-dihydrometabolites of
doxorubicin and 4'-iododoxorubicin revealed that doxoru-
bicinol was a very weak anti-proliferative agent against both
wild and doxorubicin-resistant C6 cells. In contrast, 4'-
iododoxorubicinol had retained the activity of 4'-iododoxo-
rubicin against sensitive cells and a partial activity against
doxorubicin-resistant cells; this metabolite was 200 times
more potent than doxorubicinol against sensitive cells and at
least 100 times against resistant cells.
DNA synthesis inhibition
When considering this parameter as a measure ofdrug action
(Table II), 4'-iododoxorubicin appeared as potent as doxoru-
bicin against sensitive C6 cells, while it was 20 times more
potent than doxorubicin against C6 0.5 E and C6 IDX-R
cells. In C6 sensitive cells, the dose of drug providing a 50%
inhibition of DNA synthesis was 15-80 times higher than the
dose providing a 50% inhibition of growth. In contrast, the
dose required in C6 0.5 E or C6 IDX-R resistant cells to
obtain 50% inhibition DNA synthesis was only 1-8 times
higher than the dose providing 50% inhibition of growth
(comparison of Tables I and II).
DNA synthesis inhibition induced by the 13-dihydroderi-
vatives of doxorubicin and 4'-iododoxorubicin was also
studied. Whereas doxorubicinol was almost inactive on DNA
synthesis, 4'-iododoxorubicinol had retained an appreciable
activity, although lower than that of4'-iododoxorubicin. The
doses of metabolite required for a 50% inhibition of DNA
synthesis were 50-80 times higher than those required for a
50% inhibition of growth in sensitive cells, whereas these
doses were much closer in resistant cells, as they were for the
parent compounds.
Drug incorporation
Figure I presents the incorporation of both anthracyclines in
our cellular models as a function of drug concentration.
Incorporation was linear over a wide range of extracellular
concentrations; it appears that 4'-iododoxorubicin underwent
a much higher uptake than doxorubicin in both sensitive and
resistant cells and the difference increased at high exposure
doses. As a general feature, resistant cells, selected either with
doxorubicin or with 4'-iododoxorubicin, incorporated 5-10
times less doxorubicin than sensitive cells; however, they
incorporated 4'-iododoxorubicin only 2 times less than sensi-
tive cells did.
Table II DNA synthesis inhibition of doxorubicin-sensitive and
-resistant C6 glioblastoma cells induced by doxorubicin, 4'-
iododoxurubicin and their 13-dihydroderivatives
TIC50 (AM)
C6 sensitive cells C6 0.5 E C6 IDX-R
Doxorubicin 1.98 ± 0.50 57.7 ± 2.1 20.3 ± 0.4
4'-Iododoxorubicin 1.35 ± 0.25 2.75 ± 0.58 0.85 ± 0.13
Doxorubicinol > 200 > 200
4'-Iododoxorubicinol 1.61 ± 0.56 5.36 ± 0.29
Values are means ± s.e.m. ofthree independent experiments made in
triplicate.
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Figure I Incorporation of4'-iododoxorubicin (0, *) and doxo-
rubicin (0, *) in C6 sensitive cells ( ), C6 0.5 E cells
(- - -) and C6 IDX-R cells (.....) as a function of exposure dose.
Cells were incubated for 2 h, harvested by scraping, and acid-
soluble molecules extracted with TCA. Incorporation was
evaluated by fluorometry with excitation and emission wave-
lengths set at the maximum fluorescence of each drug in the TCA
soluation.
The kinetics of drug incorporation in C6 and C6 0.5 E
cells is presented on Figure 2 for an exposure dose of
1 1sg ml '. Incorporation of 4'-iododoxorubicin was more
rapid than that of doxorubicin, and it is worth noting that
50% of the plateau level of drug incorporation in C6 sensi-
tive cells was reached in about 20 min for 4'-iododoxorubicin
and 1.5 h for doxorubicin.
The incorporation of the 13-dihydroderivative of both
drugs was studied as a function of dose in the C6 and C6 0.5
E lines (Figure 3). This incorporation was linear over a wide
range of concentrations. It appears that the incorporation of
6
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Figure 2 Kinetics of incorporation of 4'-iododoxorubicin (0,
*) and doxorubicin (0, *) in C6 sensitive ( ) and C6
0.5 E cells (- - --). Exposure dose was 1 jigml-'. Experimental
procedures were as described in Figure 1.
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and they were not present in the culture medium after
incubation; no traces of doxorubicinol could be detected on
the chromatograms of cell extracts or culture media.
4'-Iododoxorubicin also underwent a slight metabolic
transformation in cultured cells. A contaminant of the drug
preparation migrated just before 4'-iododoxorubicin in our
system and was observed in both cell extracts and media.
4'-Iododoxorubicinol was identified in cellular extracts and in
culture medium at the end of incubations; it represented
never more than 5% of the parent compound. A more polar
metabolite was detected in most samples at very low levels; it
migrated like a standard of doxorubicin and never exceeded
2% of the parent compound. No other fluorescent meta-
bolites could be detected by HPLC of cell extracts and
culture media.
Discussion
FM expo
Figure 3 Incorporation of 4'-iod
doxorubicinol (0,0) in C6 sensit
cells (---) as a function of exp
procedures were as described in F
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was 5-10 times higher in sensitil
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Figure 4 Efflux of 4'-iododoxorub
(0, *) from C6 sensitive cells (
and C6 IDX-R cells ( .....). Cells
appropriate quantities of drug in o
concentration of about IlAgmg-'
cells were reincubated without drul
by scraping and treated as descrit
sure dose We confirm in this paper the high potency of 4'-iododoxo-
rubicin as compared to doxorubicin; a similar finding has
lodoxorubicinol (0, *) and been presented in the first article concerning this drug (Bar-
Live ( ) and C6 0.5 E bieri et al., 1987). It has been shown recently that the 13-
)osure dose. The experimental dihydro-derivative of this drug was a major metabolite of
Figure 1. 4'-iododoxorubicin, especially in humans (Gianni et al., 1989;
Robert et al., 1989). It was, therefore, necessary to evaluate
of parent drugs for similar the anti-proliferative properties of this compound. It is worth
etabolites, this incorporation noting that this metabolite is a. least as potent as the parent
ve cells than in doxorubicin- drug in our model of sensitive cells, and somewhat less
'oration of 4'-iododoxorubi- potent against doxorubicin-resistant cells. It must be emphas-
loxorubicinol. ised that 4'-iododoxorubicin is still partially active on
multidrug-resistant cells that have been selected with either
doxorubicin or 4'-iododoxorubicin itself; this observation has
of course to be verified on other cellular models, but it
bicin were extruded similarly provides interesting perspectives in the clinical use of this
f 50% of the amount incor- new agent.
mnsitive cells, in 5 min for the We have shown that there is a discrepancy between the
the C6 IDX-R line (Figure doses required for DNA synthesis inhibition and for growth
inhibition in sensitive cells only, with both doxorubicin and
4'-iododoxorubicin; as already discussed (Schott & Robert,
-iododoxorubicin 1989), this suggests that different mechanisms may underlie
cytotoxicity in doxorubicin-sensitive and -resistant cell lines,
ibolites could be detected in growth inhibition being due to DNA synthesis inhibition
2 h incubation with this drug only in resistant cells. The activity of 4'-iododoxorubicin
f I and 10pgnml-'. These against C6 IDX-R cells was kept at a high level, and the
of the parent drug in terms of same discrepancy as in sensitive cells was observed between
its; they were less polar than GICso and TIC50.
times did not correspond to The link between drug incorporation and cytotoxicity was
flycones or 7-deoxyaglycones never firmly established for anthracyclines; some authors find
a good correlation between both parameters and other ob-
serve important discrepancies which are inconsistent with the
hypothesis of a causal relationship between drug incorpora-
tion and growth inhibition (Tsuruo et al., 1986). It appears
from our results that there is a reduction of drug incorpora-
tion in both resistant cell lines as usually observed (Dano,
1983); this reduction is much more important for doxoru-
bicin than for 4'-iododoxorubicin, which could explain the
low level of resistance to 4'-iododoxorubicin. Other mechan-
isms of resistance than those based upon accelerated drug
efflux might explain the distortion between reduced drug
incorporation and resistance.
Drug efflux was similar for both drugs in each cell line, its
..........
...-. rapidity being correlated with the degree of resistance of the
cells. This suggests that the differential cytotoxicity of the
-two drugs is not due to differences in the efficacy of drug
efflux; the differences observed between the incorporation of
doxorubicin and 4'-iododoxorubicin in each cell line appear
2 4 therefore related rather to drug uptake. The high lipophilicity
ours of 4'-iododoxorubicin may account for this increased rate of
..cin ..,0) and doxorubicin uptake. Irrespective to the drug, drug efflux appears to be
ii), C6 0.5 E cells (d-- )
related to the level of expression of mdrl gene in the cell line,
were incubated for 2 h with as evaluated after Northern blots; the C6 IDX-R line, which
,rder to obtain an intracellular was selected with 4'-iododoxorubicin behaves as intermediate
protein. After washing, the between the C6 wild line and the highly resistant C6 0.5 E
g for various times, harvested line selected with doxorubicin. This intermediate position is
red in Figure 1. evident when considering the degree of resistance to doxo-
10-
c
.
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rubicin and 4'-iododoxorubicin, the level of incorporation of
the drugs, the rapidity of efflux of the drugs, and the expres-
sion of mdrl gene. The lower degree of resistance of the C6
IDX-R line as compared to the C6 0.5 E line may be related
to the fact that 4'-iododoxorubicin is a weak agent for
selection of resistant lines because of its much higher activity
than doxorubicin.
It is worthwhile to emphasise that the multidrug-resistant
cells obtained after exposure to infratoxic levels of 4'-iodo-
doxorubicin remain relatively sensitive to the selecting agent,
while exhibiting an important resistance to doxorubicin. This
could be of importance in the future development of this
drug.
This work was supported by grants from the Federation Nationales
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